INSULIN

This is the translation of the article published in NOVI LIST, Rijeka, Croatia
in September 2002, under the title:

" GM INSULIN WILL DO HARM TO THE HEALTH OF DIABETICS
 AND THERE WILL BE A DEATH CASES TOO"

that I sent to Mr. Prof. Dr. Arthur Teuscher from 

"Stiftung Erhnärung und Diabetes", who supplied some data for 

this article.

 

first article about GM insulin

TO: 1 recipient

Stiftung Ernährung und Diabetes

Dear Mr. Prof. Dr. Arthur Teuscher,
below please find the first printed article.



This is the first written article:


“GM insulin will do harm to the health of diabetics
and there will be a death cases  too ”


Reading the article “ Introduction of New Insulin” in
Novi List I worried about  the monopolization of our
insulin market from the side of Novo Nordisk.  Namely,
according writing Vecernji list ( other daily)  Novo
Nordisk held up to now 85 pct of our insulin market
and in the near future, if I have understood it well,
Novo Nordisk have to rule by our market totally.  But
other matter interested me more that I haven’t find it
in there: is this product genetically altered product
because, so far I know,  Novo Nordisk produces just
the product like that.  The case is familiar to me
from Canada( by the way Canada was the first one

to extract insulin in twenties last century). There,
1995. Novo Nordisk withdrew  the all animal insulin
from the market introducing genetically altered
insulin exclusively.  This product causes at the users
the reactions that can be lethal as well.  That bad
example followed Elly Lilly 1999. so now is happening
that in Canada people can get just  the “new” product,
it means genetically altered insulin.
Of course, the producer insists that the product is
safe but it’s not so.  In April 2000.  the class suit
was launched in New Mexico,USA against both companies
because putting on the market exclusively genetically
altered insulin that causes various reactions, some of
them lethal too.

The reactions are as follows:
 A survey carried out by the Trust in 1994 showed the following adverse effects to synthetic GM insulins:

• loss of warnings of hypos
• extreme tiredness or lethargy, sleeping all the time
• large weight increase 28% - feeling unwell all the time
• memory loss, confusion, mood swings, change in personality
• erratic blood glucose levels
• joint and muscle pains
  

When patients returned to animal insulin, these symptoms largely disappeared.

Majority of the users suffers from 3 or 4 symptoms at
the same time.  There were cases that the blood sugar
dropped drastically during driving the car and people
caused the accidents, some died...  The recommendation
is for using the animal insulin further specially for
THE CHILDREN.  Returning back to the animal insulin
the symptoms withdrawing,  if there weren’t the
hypoglycemic shock and brain damages occurred. 

Just the hypoglycemic shock took 8  human lives in Canada,
92 in the USA.  All people were using, proved, GM
insulin!  The reactions appeared at 465 people, in the
USA over 4,000.  This data are coming from “ Globe and
Mail” from 6. February this year(2002).  We can expect
that, in the meantime,  this numbers will just rase up. 
Canada established  The Committee for investigation
the cases and reactions to the GM insulin.  The
details about the class suit you can find at
cfuller@telus.net,  as well you can check all above
there.
(In the meantime, the class suit is rejected due to the lack of evidences!)

I worry about that up to 27,000 our citizens will
fight against the reactions, (because at least 20 pct of GM insulin

users are suffering from the above side effects, at least, some are suffering

on multiple side effects or all of them)

  that the insulin instead
of improving their health will do more harm to them,
and there will be the death cases as well.

Sadly but true how successful is that,  as  Dr. Jost
called it “ GM imperialism”. For inst. Novo Nordisk
bought the biggest producer of the animal insulin of
the south hemisphere Biobras just to withdrew the
product from the market in favor of GM insulin.
In the lightening of all above I am afraid that our
diabetics will find themselves in the bad position
therefore I am asking from the people in charge to
take care about.

This article IS NOT THE CALL TO STOP TAKING INSULIN,

just you have to know all facts TO CHOSE THE ONE THAT SUITS YOU THE BEST!

This article was used by Mrs.Jenny Hirst from IDDT International,UK,

as one of the elements for her giving statement in front of THE PARLIAMENTARY

COMMISSION OF CANADA about side effects of insulin, 2005.

Please find the report of Mrs.Jenny Hirst, IDDT International,UK below:

Registered Charity No: 1058284  Co. Reg. No: 3148360

A charity listening to those with diabetes and their carers and supporting their needs Telephone: 01604 622837  e-mail enquiries@iddtintemational.org  website: www.iddtintemational.org Fax. 01604 622838 P 0 Box 294, Northampton, NN1 4XS

________________________________________________________________



24^th January 2005

For the attention of:

Dr. Pierre Charest
Director General
Biologics and Genetic Therapies Directorate
Health Canada



The Honorable Ujjal Dosanjh
Minister of Health and
Honorable Members of the Standing Committee on Health


Synthetic GM 'human' insulins and natural animal insulins in the UK



The Insulin Dependent Diabetes Trust is a registered charity based in the UK which  formed in 1994 to help and support people with diabetes and their families, especially those who suffer adverse effects as a result of using synthetic GM insulins. Membership of the Trust has grown with members in many countries throughout the world, largely as a result of the policy of systematic discontinuation of animal insulin by the major pharmaceutical companies in most countries, indicating that this issue is global and not restricted to any particular country. The Trust aims to help and support people who are unable to tolerate synthetic GM insulins, to seek recognition for the adverse effects caused by synthetic GM insulins and to campaign to maintain continued supplies of animal insulin.

Synthetic GM so-called 'human' insulin was introduced in the UK in 1982. Following the widespread belief, or rumour, that animal insulins were to be discontinued, by the mid to late 1980s, 84% of people requiring insulin had been transferred to GM 'human' insulin, often without their knowledge, consent or for any clinical reason. The British Diabetic Association, now Diabetes UK, received nearly 3,000 letters about adverse effects caused by this type of insulin. Many prescribing doctors prevented people from changing back to the animal insulin that had suited them better.



At that time the most common adverse effect was a loss of warnings of hypoglycaemia putting the patient at risk of unheralded hypoglycaemic attacks without the ability to take remedial action to prevent coma and even death. Since that time the range of adverse effects increased.



A survey carried out by the Trust in 1994 showed the following adverse effects to synthetic GM insulins:

• loss of warnings of hypos
• extreme tiredness or lethargy, sleeping all the time
• large weight increase 28% - feeling unwell all the time
• memory loss, confusion, mood swings, change in personality
• erratic blood glucose levels
• joint and muscle pains
  

When patients returned to animal insulin, these symptoms largely disappeared.

Patients were told that GM insulins would be cheaper, less immunogenic and better. There was never any evidence to support these statements and after 20years none of these statements have proved to be true. Indeed, it is surprising that GM insulins have become first line insulin treatment as they are significantly more expensive than animal insulins. The Trust gave evidence to the UK Health Select Committee Inquiry into the Influence of the pharmaceutical industry on health and pointed out that there was a significant waste of money to the National Health Service by the prescribing of GM insulins which no proven benefit for patients over less expensive animal insulins. [December 2004]






The evidence
A Cochrane Review [2002] comparing animal and 'human' insulin showed that 'human' insulin was not superior to animal insulin. More importantly, the Review also showed that the vast majority of the research was methodologically poor and no research had been carried out to compare mortality and complication rates using the two different types of insulin. Thus neither doctors nor patients have any evidence of long-term safety o GM insulins on which to base their treatment decisions.



The present position in the UK is that 30,000 people use animal insulin, about 10% of insulin users. However, this usage relies on patients finding out for themselves that animal insulins are available as the majority of doctors and diabetes educators do not give patients a choice of treatment which is theirs by right.



In the late 1990s insulin analogues were introduced, again on the basis that they were better than their predecessors but a second Cochrane Review [2004] compared GM 'human' insulin and short-acting insulin analogues. This review concluded that analogues are only slightly better in a minority of patients and again the research was methodologically poor and there is no evidence of their long-term safety. They have not been studied in people with diabetic complications, children or pregnant women because of concerns that insulin analogues have a greater potential for carcinogenic and mitogenic effects. It is of great concern to the Trust that patients are not informed of these risks, of the lack of research or of the lack of long-term safety data. Therefore their choice of insulin treatment is not an informed choice but one made on assumptions that insulin analogues are safe, and not on evidence of their safety.



It is for all these reasons that the Trust believes that animal insulins must remain available. If they are discontinued, people who have adverse effects to GM iinsulins will have no alternative treatment and will be condemned to a life of adverse effects. In addition, those people who do not wish to risk the possible development of cancers in the future, will not have an alternative treatment.



Lobbying Government
The Trust and its members have raised all these matters with their Members of Parliament and over 30 Parliamentary Questions have been asked by concerned MPs. The Trust has also met with The Minister of Health with responsibility for diabetes and her advisors.



To date we have established the following:

• Novo Nordisk, one of the manufacturers of GM 'human' and analogue insulins, has acknowledged that there are people who are unable to tolerate 'human' insulins.
  

• the Department of Health has acknowledged that analogue insulins do have the potential for carcinogenic effects and that GM 'human' insulins also have this potential but to a lesser degree than the analogues. It has also been  acknowledged that the epidemiological evidence gathered over 75 years does not suggest that such risks occur with natural animal insulins.
  

• The Department of Health has agreed that patients should be given an informed choice of treatment including the choice of animal insulin.
  

• The Department of Health has agreed that doctors and diabetes educators should be made more aware that animal insulins are available as a choice of treatment available to patients and arrangements are being made to provide all this information on the Department's website.
  

Patients' requests of Government
The Trust is continuing to campaign to ensure that insulin treatment is safe and effective for both short and long-term use and that the choice of treatment is available to patients. Therefore we are asking Government to:

• instigate independent, high quality, long-term research into the safety of GM 'human' and analogue insulins is carried out to ensure that these insulins are safe for long-term use for all categories of people with requiring insulin treatment.
  

• ensure that animal insulins remain available indefinitely for people who are unable to tolerate GM insulins and as a treatment option for those who have justifiable concerns about the carcinogenic and mitogenic risks associated with insulin analogues.
  

• while recognising that Government cannot interfere with the commercial decisions of pharmaceutical companies, Government is responsible for the health of British citizens and we are asking them to ensure that alternative sources of animal insulins are sought in the event that Novo Nordisk decide to discontinue availability of animal insulin in the summer of 2005, their stated time for the final decision.
  

Jenny Hirst
Founder and Co-Chairman
Insulin Dependent Diabetes Trust

Please, compare the evidences from the book

Mr. Dr.John Virapen": Side effect: Death"